RECCE PHARMACEUTICALS LTD - Announcements

Market Cap $102.0M Add to my watchlist

Healthcare

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce... An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.More

Corporate Spotlight

An Emerging Global Leader in the New Generation of Anti-Infective Therapies. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives.
View the full Corporate Spotlight

RCE receives grant from US Department of Defence

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

RCE	Ethics Approval to Start Phase 1 Intravenous Clinical Trial	PRICE SENSITIVE	25/10/21	247.07KB	Share
RCE	Reinstatement to Official Quotation	PRICE SENSITIVE	12/10/21	85.72KB	Share
RCE	Court Orders Granted	PRICE SENSITIVE	12/10/21	404.72KB	Share
RCE	Suspension from Official Quotation	PRICE SENSITIVE	12/10/21	240.35KB	Share
RCE	Trading halt	PRICE SENSITIVE	08/10/21	696.71KB	Share
RCE	Pause in Trading	PRICE SENSITIVE	08/10/21	116.55KB	Share
RCE	R327 Phase I Clinical Trial Registered on ANZCTR	PRICE SENSITIVE	30/09/21	288.3KB	Share
RCE	Appendix 4E	PRICE SENSITIVE	31/08/21	261.73KB	Share
RCE	Recce Receives Further Innovation Connections Grant	PRICE SENSITIVE	11/08/21	225.61KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	30/07/21	433.45KB	Share
RCE	Anti-Viral Patent Granted in USA for RECCE Anti-Infectives	PRICE SENSITIVE	22/07/21	270.51KB	Share
RCE	Anti-Viral Patent Granted in China	PRICE SENSITIVE	20/07/21	270.49KB	Share
RCE	Outstanding Efficacy Against Flesh-Eating Bacteria	PRICE SENSITIVE	19/07/21	423.92KB	Share
RCE	Multiple Patients Dosed in Topical Phase I/II Clinical Trial	PRICE SENSITIVE	12/07/21	296.93KB	Share
RCE	Recce Clinical Pipeline Update	PRICE SENSITIVE	07/06/21	291.67KB	Share
RCE	R327 Demonstrates World First Multiple Mechanisms of Action	PRICE SENSITIVE	27/05/21	1.26MB	Share
RCE	R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO	PRICE SENSITIVE	19/05/21	328.14KB	Share
RCE	Positive Data on RECCE 327 Against All Six ESKAPE Pathogens	PRICE SENSITIVE	04/05/21	883.37KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	27/04/21	453.68KB	Share
RCE	RECCE 327 Registered for Topical Burns Study in Humans	PRICE SENSITIVE	15/04/21	296.62KB	Share
RCE	Positive Sinusitis Patient Update - Special Access Scheme	PRICE SENSITIVE	07/04/21	300.36KB	Share
RCE	Positive Sinusitis Data Against Infection	PRICE SENSITIVE	01/04/21	618KB	Share
RCE	Anti-Viral Patent Granted in EU for RECCE Anti-Infectives	PRICE SENSITIVE	30/03/21	228.62KB	Share
RCE	S&P DJI Announces March 2021 Quarterly Rebalance	PRICE SENSITIVE	12/03/21	183.24KB	Share
RCE	Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange	PRICE SENSITIVE	08/03/21	329.63KB	Share
RCE	Appendix 4D and Half Yearly Report	PRICE SENSITIVE	25/02/21	451.22KB	Share
RCE	Recce Applies for Dual Listing on Frankfurt Stock Exchange	PRICE SENSITIVE	24/02/21	325.24KB	Share
RCE	Fiona Stanley Hospital Phase I/II Clinical Trial Agreement	PRICE SENSITIVE	16/02/21	413.46KB	Share
RCE	Further Encouraging COVID Results at Doherty	PRICE SENSITIVE	12/02/21	409.16KB	Share
RCE	R&D Incentive Rebate Received	PRICE SENSITIVE	03/02/21	324.6KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	28/01/21	531.85KB	Share
RCE	Positive Intranasal Animal Data against SARS-CoV-2 in Study	PRICE SENSITIVE	23/12/20	542.82KB	Share
RCE	RCE Awarded AusIndustry Advanced Overseas Anti-Viral Finding	PRICE SENSITIVE	08/12/20	370.39KB	Share
RCE	Recce Awarded AusIndustry Advanced Overseas (R&D) Finding	PRICE SENSITIVE	26/11/20	331.4KB	Share
RCE	Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives	PRICE SENSITIVE	23/11/20	297.82KB	Share
RCE	Reinstatement to Official Quotation	PRICE SENSITIVE	10/11/20	400.35KB	Share
RCE	Encouraging Results Against SARS-CoV-2 Virus	PRICE SENSITIVE	10/11/20	454.28KB	Share
RCE	Suspension from Official Quotation	PRICE SENSITIVE	05/11/20	422.52KB	Share
RCE	Trading Halt	PRICE SENSITIVE	03/11/20	465.12KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	21/10/20	797.75KB	Share
RCE	HREC Approval to Start Phase I/II Burns Wound Study	PRICE SENSITIVE	16/10/20	331.16KB	Share
RCE	Trading Halt	PRICE SENSITIVE	14/10/20	465.67KB	Share
RCE	Pause in trading	PRICE SENSITIVE	14/10/20	116.3KB	Share
RCE	R&D Incentive Rebate Received	PRICE SENSITIVE	05/10/20	316.17KB	Share
RCE	Murdoch Children's Research Institute, R435 Against H.Pylori	PRICE SENSITIVE	30/09/20	377.28KB	Share
RCE	Recce Completes Capital Raising of $27.95m	PRICE SENSITIVE	23/09/20	350.89KB	Share
RCE	Trading Halt	PRICE SENSITIVE	21/09/20	507.12KB	Share
RCE	R327 Phase I Study - Australia's CMAX Clinical Facility	PRICE SENSITIVE	10/09/20	377.7KB	Share
RCE	Positive & Concentration-Dependent Efficacy Against COVID-19	PRICE SENSITIVE	08/09/20	621.04KB	Share
RCE	Trading Halt	PRICE SENSITIVE	07/09/20	649.24KB	Share
RCE	Pause in Trading	PRICE SENSITIVE	07/09/20	116.3KB	Share
RCE	Recce Pharmaceuticals Receives Innovation Connections Grant	PRICE SENSITIVE	01/09/20	309.07KB	Share
RCE	Appendix 4E	PRICE SENSITIVE	28/08/20	209.81KB	Share
RCE	Recce Pharmaceuticals Appoints James Graham as CEO	PRICE SENSITIVE	28/08/20	370.03KB	Share
RCE	Positive Oral Data on New RECCE 435 Against H. pylori	PRICE SENSITIVE	04/08/20	757.45KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	31/07/20	476.79KB	Share
RCE	US Researchers to Test RECCE in Expanded SARS-CoV-2 Program	PRICE SENSITIVE	16/07/20	330.61KB	Share
RCE	Pause in Trading	PRICE SENSITIVE	16/07/20	115.78KB	Share
RCE	Reinstatement to Official Quotation	PRICE SENSITIVE	08/07/20	403.6KB	Share
RCE	RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program	PRICE SENSITIVE	08/07/20	355KB	Share
RCE	Suspension from Official Quotation	PRICE SENSITIVE	08/07/20	332.13KB	Share
RCE	Trading Halt	PRICE SENSITIVE	06/07/20	465.73KB	Share
RCE	Pause in Trading	PRICE SENSITIVE	06/07/20	115.4KB	Share
RCE	Response to ASX Price and Volume Query	PRICE SENSITIVE	27/05/20	306.58KB	Share
RCE	Positive Data on RECCE 327 Against Neisseria gonorrhoeae	PRICE SENSITIVE	04/05/20	452.72KB	Share
RCE	Appendix 4C and Activity Report	PRICE SENSITIVE	29/04/20	400.44KB	Share
RCE	Further Positive Data on RECCE 327 Against MRSA Superbug	PRICE SENSITIVE	23/04/20	875.14KB	Share
RCE	Positive Data on RECCE 327 Against Influenza A	PRICE SENSITIVE	20/04/20	573.09KB	Share
RCE	Trading Halt	PRICE SENSITIVE	16/04/20	272.42KB	Share
RCE	Recce Signs Phase I Human Clinical Trial Agreement	PRICE SENSITIVE	08/04/20	269.15KB	Share
RCE	First-in-Human Clinical Trial Progress Update	PRICE SENSITIVE	17/03/20	337.38KB	Share
RCE	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/20	387.4KB	Share
RCE	Positive Efficacy Data in Kidney/UTI infections animal model	PRICE SENSITIVE	14/02/20	551.41KB	Share
RCE	Positive Data from RECCE 327 Antibiotic Safety Studies	PRICE SENSITIVE	10/02/20	966.57KB	Share
RCE	Appendix 4C and Commentary	PRICE SENSITIVE	31/01/20	883.85KB	Share
RCE	Positive Data for RECCE 327 in MRSA Burns Wound Infection	PRICE SENSITIVE	27/11/19	712.48KB	Share
RCE	Trading Halt	PRICE SENSITIVE	25/11/19	276.11KB	Share
RCE	Appendix 4C and Commentary	PRICE SENSITIVE	31/10/19	850.63KB	Share
RCE	Recce Completes Raising of $6.76 million	PRICE SENSITIVE	10/10/19	244.08KB	Share
RCE	Trading Halt	PRICE SENSITIVE	08/10/19	421.91KB	Share
RCE	Key Family 2 Patent Granted in Japan for RECCE Antibiotics	PRICE SENSITIVE	20/09/19	238.51KB	Share
RCE	R&D Incentive Rebate Received	PRICE SENSITIVE	18/09/19	273.07KB	Share
RCE	Funding Update	PRICE SENSITIVE	11/09/19	240.9KB	Share
RCE	Appendix 4E - Preliminary Final Report	PRICE SENSITIVE	30/08/19	310.09KB	Share
RCE	FDA Positive Response for Recce Scaled Manufacture & Quality	PRICE SENSITIVE	26/08/19	253.13KB	Share
RCE	Response to ASX Appendix 4C Query	PRICE SENSITIVE	16/08/19	745.16KB	Share
RCE	Key Family 2 Patent Granted in Europe for RECCE Antibiotics	PRICE SENSITIVE	08/08/19	239.06KB	Share
RCE	Opening R&D Address at World Antibiotic Resistance Congress	PRICE SENSITIVE	01/08/19	570.79KB	Share
RCE	Appendix 4C and commentary	PRICE SENSITIVE	30/07/19	767.78KB	Share
RCE	R&D Incentive Rebate Received	PRICE SENSITIVE	30/07/19	170.61KB	Share
RCE	Appointment of Independent Chair and Additional Director	PRICE SENSITIVE	09/07/19	280.92KB	Share
RCE	Appendix 4C and commentary	PRICE SENSITIVE	29/04/19	487.15KB	Share
RCE	USA Patent Granted for Recce's Antibiotics	PRICE SENSITIVE	14/03/19	213.86KB	Share
RCE	Half Yearly Report and Accounts	PRICE SENSITIVE	27/02/19	363.14KB	Share
RCE	Recce Successfully Raises $1.8 million via Placement	PRICE SENSITIVE	08/02/19	296.72KB	Share
RCE	Trading Halt	PRICE SENSITIVE	06/02/19	272.95KB	Share
RCE	Appendix 4C and commentary	PRICE SENSITIVE	31/01/19	672.92KB	Share
RCE	R&D Incentive Rebate Received	PRICE SENSITIVE	31/01/19	218.33KB	Share
RCE	Funding Update	PRICE SENSITIVE	18/01/19	205.25KB	Share
RCE	Funding Update	PRICE SENSITIVE	18/12/18	203.36KB	Share

RCE Ethics Approval to Start Phase 1 Intravenous Clinical Trial
25/10/21	PRICE SENSITIVE	247.07KB	Share
RCE Reinstatement to Official Quotation
12/10/21	PRICE SENSITIVE	85.72KB	Share
RCE Court Orders Granted
12/10/21	PRICE SENSITIVE	404.72KB	Share
RCE Suspension from Official Quotation
12/10/21	PRICE SENSITIVE	240.35KB	Share
RCE Trading halt
08/10/21	PRICE SENSITIVE	696.71KB	Share
RCE Pause in Trading
08/10/21	PRICE SENSITIVE	116.55KB	Share
RCE R327 Phase I Clinical Trial Registered on ANZCTR
30/09/21	PRICE SENSITIVE	288.3KB	Share
RCE Appendix 4E
31/08/21	PRICE SENSITIVE	261.73KB	Share
RCE Recce Receives Further Innovation Connections Grant
11/08/21	PRICE SENSITIVE	225.61KB	Share
RCE Appendix 4C and Activity Report
30/07/21	PRICE SENSITIVE	433.45KB	Share
RCE Anti-Viral Patent Granted in USA for RECCE Anti-Infectives
22/07/21	PRICE SENSITIVE	270.51KB	Share
RCE Anti-Viral Patent Granted in China
20/07/21	PRICE SENSITIVE	270.49KB	Share
RCE Outstanding Efficacy Against Flesh-Eating Bacteria
19/07/21	PRICE SENSITIVE	423.92KB	Share
RCE Multiple Patients Dosed in Topical Phase I/II Clinical Trial
12/07/21	PRICE SENSITIVE	296.93KB	Share
RCE Recce Clinical Pipeline Update
07/06/21	PRICE SENSITIVE	291.67KB	Share
RCE R327 Demonstrates World First Multiple Mechanisms of Action
27/05/21	PRICE SENSITIVE	1.26MB	Share
RCE R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO
19/05/21	PRICE SENSITIVE	328.14KB	Share
RCE Positive Data on RECCE 327 Against All Six ESKAPE Pathogens
04/05/21	PRICE SENSITIVE	883.37KB	Share
RCE Appendix 4C and Activity Report
27/04/21	PRICE SENSITIVE	453.68KB	Share
RCE RECCE 327 Registered for Topical Burns Study in Humans
15/04/21	PRICE SENSITIVE	296.62KB	Share
RCE Positive Sinusitis Patient Update - Special Access Scheme
07/04/21	PRICE SENSITIVE	300.36KB	Share
RCE Positive Sinusitis Data Against Infection
01/04/21	PRICE SENSITIVE	618KB	Share
RCE Anti-Viral Patent Granted in EU for RECCE Anti-Infectives
30/03/21	PRICE SENSITIVE	228.62KB	Share
RCE S&P DJI Announces March 2021 Quarterly Rebalance
12/03/21	PRICE SENSITIVE	183.24KB	Share
RCE Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange
08/03/21	PRICE SENSITIVE	329.63KB	Share
RCE Appendix 4D and Half Yearly Report
25/02/21	PRICE SENSITIVE	451.22KB	Share
RCE Recce Applies for Dual Listing on Frankfurt Stock Exchange
24/02/21	PRICE SENSITIVE	325.24KB	Share
RCE Fiona Stanley Hospital Phase I/II Clinical Trial Agreement
16/02/21	PRICE SENSITIVE	413.46KB	Share
RCE Further Encouraging COVID Results at Doherty
12/02/21	PRICE SENSITIVE	409.16KB	Share
RCE R&D Incentive Rebate Received
03/02/21	PRICE SENSITIVE	324.6KB	Share
RCE Appendix 4C and Activity Report
28/01/21	PRICE SENSITIVE	531.85KB	Share
RCE Positive Intranasal Animal Data against SARS-CoV-2 in Study
23/12/20	PRICE SENSITIVE	542.82KB	Share
RCE RCE Awarded AusIndustry Advanced Overseas Anti-Viral Finding
08/12/20	PRICE SENSITIVE	370.39KB	Share
RCE Recce Awarded AusIndustry Advanced Overseas (R&D) Finding
26/11/20	PRICE SENSITIVE	331.4KB	Share
RCE Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives
23/11/20	PRICE SENSITIVE	297.82KB	Share
RCE Reinstatement to Official Quotation
10/11/20	PRICE SENSITIVE	400.35KB	Share
RCE Encouraging Results Against SARS-CoV-2 Virus
10/11/20	PRICE SENSITIVE	454.28KB	Share
RCE Suspension from Official Quotation
05/11/20	PRICE SENSITIVE	422.52KB	Share
RCE Trading Halt
03/11/20	PRICE SENSITIVE	465.12KB	Share
RCE Appendix 4C and Activity Report
21/10/20	PRICE SENSITIVE	797.75KB	Share
RCE HREC Approval to Start Phase I/II Burns Wound Study
16/10/20	PRICE SENSITIVE	331.16KB	Share
RCE Trading Halt
14/10/20	PRICE SENSITIVE	465.67KB	Share
RCE Pause in trading
14/10/20	PRICE SENSITIVE	116.3KB	Share
RCE R&D Incentive Rebate Received
05/10/20	PRICE SENSITIVE	316.17KB	Share
RCE Murdoch Children's Research Institute, R435 Against H.Pylori
30/09/20	PRICE SENSITIVE	377.28KB	Share
RCE Recce Completes Capital Raising of $27.95m
23/09/20	PRICE SENSITIVE	350.89KB	Share
RCE Trading Halt
21/09/20	PRICE SENSITIVE	507.12KB	Share
RCE R327 Phase I Study - Australia's CMAX Clinical Facility
10/09/20	PRICE SENSITIVE	377.7KB	Share
RCE Positive & Concentration-Dependent Efficacy Against COVID-19
08/09/20	PRICE SENSITIVE	621.04KB	Share
RCE Trading Halt
07/09/20	PRICE SENSITIVE	649.24KB	Share
RCE Pause in Trading
07/09/20	PRICE SENSITIVE	116.3KB	Share
RCE Recce Pharmaceuticals Receives Innovation Connections Grant
01/09/20	PRICE SENSITIVE	309.07KB	Share
RCE Appendix 4E
28/08/20	PRICE SENSITIVE	209.81KB	Share
RCE Recce Pharmaceuticals Appoints James Graham as CEO
28/08/20	PRICE SENSITIVE	370.03KB	Share
RCE Positive Oral Data on New RECCE 435 Against H. pylori
04/08/20	PRICE SENSITIVE	757.45KB	Share
RCE Appendix 4C and Activity Report
31/07/20	PRICE SENSITIVE	476.79KB	Share
RCE US Researchers to Test RECCE in Expanded SARS-CoV-2 Program
16/07/20	PRICE SENSITIVE	330.61KB	Share
RCE Pause in Trading
16/07/20	PRICE SENSITIVE	115.78KB	Share
RCE Reinstatement to Official Quotation
08/07/20	PRICE SENSITIVE	403.6KB	Share
RCE RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program
08/07/20	PRICE SENSITIVE	355KB	Share
RCE Suspension from Official Quotation
08/07/20	PRICE SENSITIVE	332.13KB	Share
RCE Trading Halt
06/07/20	PRICE SENSITIVE	465.73KB	Share
RCE Pause in Trading
06/07/20	PRICE SENSITIVE	115.4KB	Share
RCE Response to ASX Price and Volume Query
27/05/20	PRICE SENSITIVE	306.58KB	Share
RCE Positive Data on RECCE 327 Against Neisseria gonorrhoeae
04/05/20	PRICE SENSITIVE	452.72KB	Share
RCE Appendix 4C and Activity Report
29/04/20	PRICE SENSITIVE	400.44KB	Share
RCE Further Positive Data on RECCE 327 Against MRSA Superbug
23/04/20	PRICE SENSITIVE	875.14KB	Share
RCE Positive Data on RECCE 327 Against Influenza A
20/04/20	PRICE SENSITIVE	573.09KB	Share
RCE Trading Halt
16/04/20	PRICE SENSITIVE	272.42KB	Share
RCE Recce Signs Phase I Human Clinical Trial Agreement
08/04/20	PRICE SENSITIVE	269.15KB	Share
RCE First-in-Human Clinical Trial Progress Update
17/03/20	PRICE SENSITIVE	337.38KB	Share
RCE Half Yearly Report and Accounts
27/02/20	PRICE SENSITIVE	387.4KB	Share
RCE Positive Efficacy Data in Kidney/UTI infections animal model
14/02/20	PRICE SENSITIVE	551.41KB	Share
RCE Positive Data from RECCE 327 Antibiotic Safety Studies
10/02/20	PRICE SENSITIVE	966.57KB	Share
RCE Appendix 4C and Commentary
31/01/20	PRICE SENSITIVE	883.85KB	Share
RCE Positive Data for RECCE 327 in MRSA Burns Wound Infection
27/11/19	PRICE SENSITIVE	712.48KB	Share
RCE Trading Halt
25/11/19	PRICE SENSITIVE	276.11KB	Share
RCE Appendix 4C and Commentary
31/10/19	PRICE SENSITIVE	850.63KB	Share
RCE Recce Completes Raising of $6.76 million
10/10/19	PRICE SENSITIVE	244.08KB	Share
RCE Trading Halt
08/10/19	PRICE SENSITIVE	421.91KB	Share
RCE Key Family 2 Patent Granted in Japan for RECCE Antibiotics
20/09/19	PRICE SENSITIVE	238.51KB	Share
RCE R&D Incentive Rebate Received
18/09/19	PRICE SENSITIVE	273.07KB	Share
RCE Funding Update
11/09/19	PRICE SENSITIVE	240.9KB	Share
RCE Appendix 4E - Preliminary Final Report
30/08/19	PRICE SENSITIVE	310.09KB	Share
RCE FDA Positive Response for Recce Scaled Manufacture & Quality
26/08/19	PRICE SENSITIVE	253.13KB	Share
RCE Response to ASX Appendix 4C Query
16/08/19	PRICE SENSITIVE	745.16KB	Share
RCE Key Family 2 Patent Granted in Europe for RECCE Antibiotics
08/08/19	PRICE SENSITIVE	239.06KB	Share
RCE Opening R&D Address at World Antibiotic Resistance Congress
01/08/19	PRICE SENSITIVE	570.79KB	Share
RCE Appendix 4C and commentary
30/07/19	PRICE SENSITIVE	767.78KB	Share
RCE R&D Incentive Rebate Received
30/07/19	PRICE SENSITIVE	170.61KB	Share
RCE Appointment of Independent Chair and Additional Director
09/07/19	PRICE SENSITIVE	280.92KB	Share
RCE Appendix 4C and commentary
29/04/19	PRICE SENSITIVE	487.15KB	Share
RCE USA Patent Granted for Recce's Antibiotics
14/03/19	PRICE SENSITIVE	213.86KB	Share
RCE Half Yearly Report and Accounts
27/02/19	PRICE SENSITIVE	363.14KB	Share
RCE Recce Successfully Raises $1.8 million via Placement
08/02/19	PRICE SENSITIVE	296.72KB	Share
RCE Trading Halt
06/02/19	PRICE SENSITIVE	272.95KB	Share
RCE Appendix 4C and commentary
31/01/19	PRICE SENSITIVE	672.92KB	Share
RCE R&D Incentive Rebate Received
31/01/19	PRICE SENSITIVE	218.33KB	Share
RCE Funding Update
18/01/19	PRICE SENSITIVE	205.25KB	Share
RCE Funding Update
18/12/18	PRICE SENSITIVE	203.36KB	Share

REFRESH

First 2

(20min delay)
Last 46.0¢		Change 0.000(0.00%)		Mkt cap ! $102.0M

Open	High	Low	Value	Volume
46.0¢	46.5¢	46.0¢	$19.60K	42.56K

Buyers (Bids)

No.	Vol.	Price($)
3	41004	46.0¢

Sellers (Offers)

Price($)	Vol.	No.
46.5¢	38272	2

View Market Depth

No.	Vol.	Price($)
1	4993	0.460
6	185159	0.455
12	216338	0.450
2	110000	0.445
5	121417	0.440

Price($)	Vol.	No.
0.465	38272	2
0.470	43385	4
0.475	32507	2
0.480	16600	1
0.485	82243	1

Last trade - 15.56pm 26/07/2024 (20 minute delay)


Last 46.0¢		Change 0.000 ( 1.08 %)
Open	High	Low	Volume
46.0¢	47.0¢	46.0¢	5566
Last updated 12.56pm 26/07/2024 ?

RCE (ASX) Chart

RECCE PHARMACEUTICALS LTD - Announcements

Corporate Spotlight

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories